The expert delegation of the Ministry of Health, Labor and Welfare of Japan approved the use of rheumatoid arthritis drug “Baricitinib” in the treatment of the new type of corona virus (Covid-19).
According to the Kyodo agency, the rheumatic arthritis drug “Baricitinib”, produced by the US Eli Lily, was approved by the expert health delegation under the ministry.
The company applied to the ministry for approval of the drug in December. The ministry is expected to officially approve the use of the drug within a month.
“Baricitinib” was approved for use in addition to the anti-viral drug “Remdesivir” in the treatment of Covid-19 patients in need of oxygen supplementation in the USA.
The government of Japan has so far approved the drugs “Remdesivir” and “steroid dexamethasone” in the treatment of Kovid-19.
Download the NTV application, be informed about the developments
PERMANENT ODOR AND HEARING LOSS IN VIRUS